Scientists hunt for better ways to track rare immune disease
NCT ID NCT06694363
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aims to find new biomarkers to better screen and monitor Activated PI3K Delta Syndrome (APDS), a rare immune disorder. Researchers will collect blood, urine, and stool samples from 14 APDS patients over two years to analyze changes in immune cells and other markers. The goal is to improve disease tracking and treatment monitoring, not to test a new drug.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to better ways to diagnose and monitor APDS, helping doctors tailor treatments more effectively.
- What could go wrong
- This is a very small, early-stage study with only 14 participants, so results may not apply broadly. It focuses on finding biomarkers, not testing a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACTIVATED PHOSPHOINOSITIDE 3-KINASE Δ SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU IUCT Oncopole - TOULOUSE
NOT_YET_RECRUITINGToulouse, France
-
Hôpital Haut Levêque - BORDEAUX
NOT_YET_RECRUITINGBordeaux, 33000, France
-
Hôpital Jeanne de Flandres - LILLE
RECRUITINGLille, 59000, France
-
Hôpital La Timone adulte - MARSEILLE
NOT_YET_RECRUITINGMarseille, 13000, France
-
Hôpital Necker Enfants Malades - PARIS
RECRUITINGParis, 75015, France
-
Hôpital Pellerin Enfants - BORDEAUX
NOT_YET_RECRUITINGBordeaux, 33000, France
-
Hôpital des enfants - TOULOUSE
NOT_YET_RECRUITINGToulouse, France